ASH 2022 | Phase I study of Bgb-11417 alone or with zanubrutinib in patients with NHL, WM, and CLL/SLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, highlights results from a Phase I study investigating sonrotoclax (NCT04277637), a highly potent Bcl-2 inhibitor, in hematological malignancies. Preliminary data indicate an encouraging safety profile and preliminary evidence of efficacy for this agent across all histologies and dose levels tested. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Beigene: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; LOXO: Honoraria; AstraZeneca: Honoraria; Janssen: Honoraria, Research Funding.
